RecruitingInterventionalPhase 1Last updated May 28, 2026

A Study to Test How Different Doses of BI 3814916 Are Tolerated by Healthy People

A Phase 1, Randomised, Single-blind, Placebo-controlled Trial to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BI 3814916 in Healthy Male and Female Subjects

Overview

ClinicalTrials.gov ID: NCT07486115
Lead Sponsor: Boehringer IngelheimINDUSTRY
Brief Summary: The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3814916 in healthy male and female trial participants.
Study Type: Interventional

Secondary IDs

2025-523262-25-00EU Trial (CTIS) Number

1111-1325-7389Registry Identifier

WHO - International Clinical Trials Registry Platform (ICTRP)

Status

Overall Status: Recruiting
Start Date: May 20, 2026Actual
Primary Completion Date: Jul 12, 2027Estimated
Completion Date: Jul 12, 2027Estimated

Study Record Dates

First Submitted: Mar 17, 2026
First Submitted that Met QC Criteria: Mar 17, 2026
First Posted: Mar 20, 2026Actual
Last Update Submitted that Met QC Criteria: May 26, 2026
Last Update Posted: May 28, 2026Actual
Last Verified: May 2026

NCT06631430Completed

A Study to Test How Well Different Doses of BI 3810477 Are Tolerated by Healthy Men

NCT06984926Completed

A Study to Test How Well Multiple Doses of BI 3810477 Are Tolerated by Healthy Adults

NCT07526194Active, not recruiting

A Study in Healthy Men to Test How Well Different Doses of BI 3821001 Are Tolerated

NCT06081530Completed

A Study in Healthy Men to Test How Well Different Doses of BI 3802876 Are Tolerated

NCT05857878Completed

A Study to Test How Well Different Doses of BI 1815368 Are Tolerated by Healthy Men

NCT05934955Completed

A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0003)